Psoriasis is a common, chronic disease which affects nearly 3% of the population. The lifetime incidence of nail involvement increases up to 80–90% for psoriatic patients. Nail psoriasis is considered a significant social problem. Many topical agents have been used for psoriatic nails with various side effects and some benefits; management is currently inconclusive. Methotrexate (MTX) is a folic acid analog, which irreversibly binds to dehydrofolate reductase and blocks deoxyribonucleic acid synthesis. It is considered a potential treatment option for rapidly growing cells and has an anti-inflammatory effect through inhibition of the polyamine pathway in autoimmune diseases. Intralesional MTX has been used successfully for various indications. We present a case successfully treated with low-dose intralesional MTX with no observed side effects in a 26-year-old female psoriatic patient suffering from nail dystrophy. In contrast, conventional topical and systemic therapies have various side effects, which limit their use. We conclude that intralesional MTX injection seems to be a safe and effective treatment option for nail psoriasis; however, large controlled studies are needed.

Keywords:
Intralesional methotrexate, Nail psoriasis
1.
Gaspari AA: Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006;54(suppl 2):S67–S80.
2.
McGonagle D, Tan AL, Benjamin M: The nail as a musculoskeletal appendage – implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009;218:97–102.
3.
De Berker D: Management of psoriatic nail disease. Semin Cutan Med Surg 2009;28:39–43.
4.
Chan ES, Cronstein BN: Methotrexate – how does it really work? Nat Rev Rheumatol 2010;6:175–178.
5.
Agostini A, De Lapparent T, Collette E, et al: In situ methotrexate injection for treatment of recurrent endometriotic cysts. Eur J Obstet Gynecol Reprod Biol 2007;130:129–131.
6.
De Jong EM, Seegers BA, Gulinck MK, et al: Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996;193:300–303.
7.
Fernández-Guarino M, Harto A, Sánchez-Ronco M, et al: Pulsed dye laser vs photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study. J Eur Acad Dermatol Venereol 2009;23:891–895.
8.
Wolf R, Tur E, Brenner S: Corticosteroid-induced ‘disappearing digit’. J Am Acad Dermatol 1990;23:755–756.
9.
Lee JY: Severe 20-nail psoriasis successfully treated by low dose methotrexate. Dermatol Online J 2009;15:8.
10.
Mahrle G, Schulze HJ, Farber L, et al: Low dose short term cyclosporine versus etretinate in psoriasis: improvement of skin, nail and joint involvement J Am Acad Dermatol 1995;32:78–88.
11.
McGonagle D, Palmou Fontana N, Tan AL, Benjamin M: Nailing down the genetic and immunological basis for psoriatic disease. Dermatology 2010;221(suppl 1):15–22.
12.
Jiaravuthisan MM, Sasseville D, Vender RB, et al: Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1–27.
13.
Gerstein W: Psoriasis and lichen planus of nails: treatment with triamcinolone. Arch Dermatol 1962;86:419–421.
14.
Cohen PR, Schulze KE, Teller CF, et al: Intralesional methotrexate for keratoacanthoma of the nose. Skinmed 2005;4:393–395.
15.
Annest NM, Van Beek MJ, Arpey CJ, Whitaker DC: Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature. J Am Acad Dermatol 2007;56:989–993.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.